软组织填充剂致视力丧失管理共识意见
该共识意见针对软组织填充剂注射后视力丧失(STFIVL)的即时管理,指出目前尚无国际公认共识。近期系统评价认为证据不足以支持球后透明质酸酶,替代治疗需探索;现有文献显示球后和球周透明质酸酶逆转视力丧失的成功不一致且未经证实,当前证据基础不支持使用,且对非眼科培训医师可能增加严重不良事件风险。作者因此为眼科和非眼科培训医师推荐两条替代治疗路径,强调临床医师须迅速行动并立即转至急诊科或眼科专科机构,非眼科培训医师的干预应围绕立即使用非侵入性技术。
要点
- 临床医师必须迅速行动,立即将患者转至急诊科或眼科专科机构,以争取最佳视力恢复机会。
- 当前证据基础不支持使用球后和球周透明质酸酶;其疗效未经证实,文献证据混杂。
- 当前证据提示球后透明质酸酶可能增加严重不良事件风险,对非眼科培训医师可能加重问题。
- 作者为眼科和非眼科培训医师分别推荐两条替代治疗路径。
- 非眼科培训医师的干预重点应围绕立即使用非侵入性技术。
适用人群与场景
- 软组织填充剂注射后发生视力丧失的患者
- 眼科培训医师与非眼科培训医师(分别适用不同治疗路径)
处置流程与药物剂量
- 临床医师必须迅速行动,安排立即转至急诊科或眼科专科机构。
- 非眼科培训医师的干预重点应围绕立即使用非侵入性技术。
- 作者为眼科培训医师推荐一条替代治疗路径,为非眼科培训医师推荐另一条替代治疗路径(原文未给出路径具体步骤)。
- 当前证据基础不支持使用球后和球周透明质酸酶。
红旗征与不能漏的情况
- 软组织填充剂注射后视力丧失需立即转至急诊科或眼科专科机构,不能延误。
- 球后透明质酸酶可能增加严重不良事件风险,对非眼科培训医师可能加重问题。
研究设计与关键结果
- 该文献为共识意见,旨在理解STFIVL的病理生理、识别体征和症状,并为非眼科和眼科培训医师提出视力丧失管理算法。
- 近期系统评价文献结论认为,证据不足以支持球后透明质酸酶,替代治疗需探索。
- 现有文献显示球后和球周透明质酸酶逆转软组织填充剂所致视力丧失的成功不一致且未经证实;多种治疗用于辅助逆转视力丧失但结局不一。
- 球后透明质酸酶用于逆转STFIVL存在争议,疗效未经证实,文献证据混杂。
证据类型、等级与局限
- 证据类型:共识意见。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议:临床医师必须迅速行动,立即将STFIVL患者转至急诊科或眼科专科机构。
- 作者建议:非眼科培训医师的干预应围绕立即使用非侵入性技术。
- 作者认为当前证据基础不支持使用球后和球周透明质酸酶,且球后透明质酸酶可能增加严重不良事件风险,对非眼科培训医师可能加重问题。
- 作者为眼科和非眼科培训医师分别推荐两条替代治疗路径。
指南或共识出处
- J Clin Aesthet Dermatol 发表的《软组织填充剂致视力丧失管理共识意见》
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
There are multiple treatment strategies proposed for the management of vision loss related to the injection of soft tissue fillers. Currently, there is no internationally accepted consensus on the immediate management of soft tissue filler induced vision loss (STFIVL). A recent systematic review of the literature concluded that there is not enough evidence to support retrobulbar hyaluronidase, and alternative treatments require exploration. The available literature demonstrates the inconsistent and unproven success of retrobulbar and peribulbar hyaluronidase in reversal of soft filler induced vision loss. Various therapeutics have been used to aid the reversal of vision loss but with mixed outcomes. The current evidence base does not support the use of retrobulbar and peribulbar hyaluronidase. The use of retrobulbar hyaluronidase for reversing soft tissue filler induced vision loss is controversial. Its efficacy remains unproven and there is mixed evidence within the literature. The current evidence suggests that there may be an increased risk of introducing severe adverse events associated with retrobulbar hyaluronidase and may even exacerbate the problem for those clinicians who are not ophthalmology trained. Therefore, we recommend two alternative treatment pathways for ophthalmology and non-ophthalmology trained practitioners. The suggested goal of this publication is to understand the pathophysiology of STFIVL, recognize signs and symptoms, and to propose algorithms to manage vision loss for both non-ophthalmology and ophthalmology trained clinicians. Clinicians must act swiftly and arrange immediate transfer to an emergency department or ophthalmology specialist setting to give the patient the best chance of vision restoration. The focus of any intervention for non-ophthalmology trained clinicians should be based around the immediate use of non-invasive techniques.
参考来源
- Walker L, Convery C, Davies E, et al. Consensus Opinion for The Management of Soft Tissue Filler Induced Vision Loss. J Clin Aesthet Dermatol. 2021. PMID: 35096260
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。